{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:59:25Z","timestamp":1787169565030,"version":"build-2736575974"},"reference-count":42,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2025.12860","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T02:10:06Z","timestamp":1743732606000},"page":"1-9","source":"Crossref","is-referenced-by-count":3,"title":["Repurposing of the Syk inhibitor fostamatinib using a machine learning algorithm"],"prefix":"10.3892","volume":"29","author":[{"given":"Yoonjung","family":"Choi","sequence":"first","affiliation":[{"name":"Deargen Inc., Daejeon 35220, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejin","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Ram","family":"Beck","sequence":"additional","affiliation":[{"name":"Deargen Inc., Daejeon 35220, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Lee","sequence":"additional","affiliation":[{"name":"Deargen Inc., Daejeon 35220, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoree","family":"Kim","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Chun","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sung","family":"Won","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Ho","family":"Ko","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"key20250513112334_b1-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrc3847","article-title":"The TAM family: Phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer","volume":"14","author":"Graham","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"key20250513112334_b2-ETM-29-6-12860","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0769-1","article-title":"Targeting Gas6\/TAM in cancer cells and tumor microenvironment","volume":"17","author":"Wu","year":"2018","journal-title":"Mol Cancer"},{"key":"key20250513112334_b3-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nri2303","article-title":"Immunobiology of the TAM receptors","volume":"8","author":"Lemke","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"key20250513112334_b4-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1172\/JCI67655","article-title":"MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis","volume":"123","author":"Cook","year":"2013","journal-title":"J Clin Invest"},{"key":"key20250513112334_b5-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nature12998","article-title":"The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells","volume":"507","author":"Paolino","year":"2014","journal-title":"Nature"},{"key":"key20250513112334_b6-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00281-018-0698-5","article-title":"Efferocytosis in the tumor microenvironment","volume":"40","author":"Werfel","year":"2018","journal-title":"Semin Immunopathol"},{"key":"key20250513112334_b7-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"8818","DOI":"10.18632\/oncotarget.2422","article-title":"Axl as a mediator of cellular growth and survival","volume":"5","author":"Axelrod","year":"2014","journal-title":"Oncotarget"},{"key":"key20250513112334_b8-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1158\/0008-5472.CAN-09-2997","article-title":"R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer","volume":"70","author":"Holland","year":"2010","journal-title":"Cancer Res"},{"key":"key20250513112334_b9-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"78653","DOI":"10.18632\/oncotarget.11823","article-title":"Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy","volume":"7","author":"Crittenden","year":"2016","journal-title":"Oncotarget"},{"key":"key20250513112334_b10-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1158\/0008-5472.CAN-17-1973","article-title":"Small-molecule inhibition of Axl targets tumor immune suppression and enhances chemotherapy in pancreatic cancer","volume":"78","author":"Ludwig","year":"2018","journal-title":"Cancer Res"},{"key":"key20250513112334_b11-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"105727","DOI":"10.18632\/oncotarget.22394","article-title":"MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"key20250513112334_b12-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1158\/1535-7163.MCT-15-0116","article-title":"Small molecule inhibition of MERTK is efficacious in non-small cell lung cancer models independent of driver oncogene status","volume":"14","author":"Cummings","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"key20250513112334_b13-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/bjc.2016.428","article-title":"Giving AXL the axe: Targeting AXL in human malignancy","volume":"116","author":"Gay","year":"2017","journal-title":"Br J Cancer"},{"key":"key20250513112334_b14-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"7031","DOI":"10.1021\/jm500749d","article-title":"UNC2025, a potent and orally bioavailable MER\/FLT3 dual inhibitor","volume":"57","author":"Zhang","year":"2014","journal-title":"J Med Chem"},{"key":"key20250513112334_b15-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1158\/1078-0432.CCR-16-1330","article-title":"UNC2025, a MERTK small-molecule inhibitor, is therapeutically effective alone and in combination with methotrexate in leukemia models","volume":"23","author":"DeRyckere","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20250513112334_b16-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1158\/1535-7163.MCT-17-1239","article-title":"MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents","volume":"17","author":"McDaniel","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"598477","key":"key20250513112334_b17-ETM-29-6-12860","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.598477","article-title":"A potent and selective dual inhibitor of AXL and MERTK possesses both immunomodulatory and tumor-targeted activity","volume":"10","author":"Rios-Doria","year":"2020","journal-title":"Front Oncol"},{"key":"key20250513112334_b18-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41563-019-0338-z","article-title":"Exploiting machine learning for end-to-end drug discovery and development","volume":"18","author":"Ekins","year":"2019","journal-title":"Nat Mater"},{"key":"key20250513112334_b19-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.semcancer.2019.12.011","article-title":"Machine and deep learning approaches for cancer drug repurposing","volume":"68","author":"Issa","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"key20250513112334_b20-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"D1045","DOI":"10.1093\/nar\/gkv1072","article-title":"BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology","volume":"44 (D1)","author":"Gilson","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"key20250513112334_b21-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"D1102","DOI":"10.1093\/nar\/gky1033","article-title":"PubChem 2019 update: Improved access to chemical data","volume":"47 (D1)","author":"Kim","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"key20250513112334_b22-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"D1100","DOI":"10.1093\/nar\/gkr777","article-title":"ChEMBL: A large-scale bioactivity database for drug discovery","volume":"40 (Database Issue)","author":"Gaulton","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"key20250513112334_b23-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.csbj.2020.03.025","article-title":"Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model","volume":"18","author":"Beck","year":"2020","journal-title":"Comput Struct Biotechnol J"},{"issue":"1325","key":"key20250513112334_b24-ETM-29-6-12860","doi-asserted-by":"publisher","DOI":"10.3390\/v12111325","article-title":"Target-centered drug repurposing predictions of human angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine subtype 2 (TMPRSS2) interacting approved drugs for coronavirus disease 2019 (COVID-19) treatment through a drug-target interaction deep learning model","volume":"12","author":"Choi","year":"2020","journal-title":"Viruses"},{"key":"key20250513112334_b25-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1182\/blood-2018-11-852491","article-title":"Fostamatinib for the treatment of chronic immune thrombocytopenia","volume":"133","author":"Connell","year":"2019","journal-title":"Blood"},{"key":"key20250513112334_b26-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/database\/bay083","article-title":"Drug target commons 2.0: A community platform for systematic analysis of drug-target interaction profiles","volume":"2018","author":"Tanoli","year":"2018","journal-title":"Database (Oxford)"},{"key":"key20250513112334_b27-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"D198","DOI":"10.1093\/nar\/gkl999","article-title":"BindingDB: A web-accessible database of experimentally determined protein-ligand binding affinities","volume":"35 (Database Issue)","author":"Liu","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"key20250513112334_b28-ETM-29-6-12860","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.aiopen.2021.01.001","article-title":"Graph neural networks: A review of methods and applications","volume":"1","author":"Zhou","year":"2020","journal-title":"AI Open"},{"key":"key20250513112334_b29-ETM-29-6-12860","author":"Elnaggar"},{"key":"key20250513112334_b30-ETM-29-6-12860","author":"Ruder"},{"key":"key20250513112334_b31-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gku476","article-title":"LINCS canvas browser: Interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures","volume":"42 (Web Server Issue)","author":"Duan","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"key20250513112334_b32-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"key20250513112334_b33-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A next generation connectivity map: L1000 platform and the first 1,000,000 profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"issue":"e630","key":"key20250513112334_b34-ETM-29-6-12860","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000630","article-title":"AXL inhibition represents a novel therapeutic approach in BCR-ABL negative myeloproliferative neoplasms","volume":"5","author":"Beitzen-Heineke","year":"2021","journal-title":"Hemasphere"},{"issue":"5639","key":"key20250513112334_b35-ETM-29-6-12860","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225639","article-title":"Targeting MERTK and AXL in EGFR mutant non-small cell lung cancer","volume":"13","author":"Yan","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20250513112334_b36-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40265-018-0927-1","article-title":"Fostamatinib: First global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"key20250513112334_b37-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"issue":"2730","key":"key20250513112334_b38-ETM-29-6-12860","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102730","article-title":"Transcriptomics-based drug repurposing approach identifies novel drugs against sorafenib-resistant hepatocellular carcinoma","volume":"12","author":"Regan-Fendt","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1195","key":"key20250513112334_b39-ETM-29-6-12860","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061195","article-title":"TAM receptor inhibition-implications for cancer and the immune system","volume":"13","author":"Aehnlich","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20250513112334_b40-ETM-29-6-12860","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1158\/0008-5472.CAN-18-2614","article-title":"Pan-TAM tyrosine kinase inhibitor BMS-777607 enhances anti-PD-1 mAb efficacy in a murine model of triple-negative breast cancer","volume":"79","author":"Kasikara","year":"2019","journal-title":"Cancer Res"},{"key":"key20250513112334_b41-ETM-29-6-12860","first-page":"1466","article-title":"Axl inhibitor R428 induces apoptosis of cancer cells by blocking lysosomal acidification and recycling independent of Axl inhibition","volume":"8","author":"Chen","year":"2018","journal-title":"Am J Cancer Res"},{"issue":"59","key":"key20250513112334_b42-ETM-29-6-12860","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-019-0377-8","article-title":"Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation","volume":"17","author":"Lauter","year":"2019","journal-title":"Cell Commun Signal"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T04:23:38Z","timestamp":1747110218000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2025.12860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,4,4]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2025.12860","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]}}}